Interpretation of the global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

CHEN Maoshan ,  LV Qing

Department of Breast Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China;

Corresponding?author：

LV Qing, Email: lqlq1963@163.com

Keywords：

Breast cancer; morbidity; death; risk factor; prevention; guideline interpretation

DOI：

10.7507/1007-4848.202112063

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Recently, the National Cancer Center analyzed the disease burden and epidemiological trend of breast cancer based on the global population registration data, providing important reference for the prevention and control of breast cancer and health decision-making. Based on the current situation of prevention and control of breast cancer in China, this paper briefly interpreted the key points of the disease burden and trend of breast cancer.

Citation： CHEN Maoshan, LV Qing. Interpretation of the global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2022, 29(4): 401-406. doi: 10.7507/1007-4848.202112063 Copy

1.	Bray F, Laversanne M, Weiderpass E, et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer, 2021, 127(16): 3029-3030.
2.	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
3.	Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (Lond), 2021, 41(11): 1183-1194.
4.	鄒小農, 賈漫漫, 王鑫, 等. 《2020全球癌癥報告》要點解讀. 中國胸心血管外科臨床雜志, 2021, 28(1): 11-18.
5.	United Nations Development Program. Human Development Report 2018: Human Development for Everyone. New York, NY: United Nations Development Program, 2018. 22-33.
6.	Soerjomataram I, Bray F. Planning for tomorrow: Global cancer incidence and the role of prevention 2020-2070. Nat Rev Clin Oncol, 2021, 18(10): 663-672.
7.	Lawson MB, Lee CI, Hippe DS, et al. Receipt of screening mammography by insured women diagnosed with breast cancer and impact on outcomes. J Natl Compr Canc Netw, 2021, Online ahead of print.
8.	Duffy SW, Vulkan D, Cuckle H, et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): Final results of a randomised, controlled trial. Lancet Oncol, 2020, 21(9): 1165-1172.
9.	Harkness EF, Astley SM, Evans DG. Risk-based breast cancer screening strategies in women. Best Pract Res Clin Obstet Gynaecol, 2020, 65: 3-17.
10.	Kresovich JK, Xu Z, O'Brien KM, et al. Methylation-based biological age and breast cancer risk. J Natl Cancer Inst, 2019, 111(10): 1051-1058.
11.	Pfeiffer RM, Webb-Vargas Y, Wheeler W, et al. Proportion of U. S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev, 2018, 27(10): 1214-1222.
12.	Nguyen TL, Li S, Dite GS, et al. Interval breast cancer risk associations with breast density, family history and breast tissue aging. Int J Cancer, 2020, 147(2): 375-382.
13.	Kim YY, Kang HJ, Ha S, et al. Effects of living in the same region as one’s workplace on the total fertility rate of working women in Korea. Epidemiol Health, 2019, 41: e2019043.
14.	Zhang Q, Liu LY, Wang F, et al. The changes in female physical and childbearing characteristics in China and potential association with risk of breast cancer. BMC Public Health, 2012, 12: 368.
15.	Gray JM, Rasanayagam S, Engel C, et al. State of the evidence 2017: An update on the connection between breast cancer and the environment. Environ Health, 2017, 16(1): 94.
16.	Rudel RA, Fenton SE, Ackerman JM, et al. Environmental exposures and mammary gland development: State of the science, public health implications, and research recommendations. Environ Health Perspect, 2011, 119(8): 1053-1061.
17.	Teitelbaum SL, Belpoggi F, Reinlib L. Advancing research on endocrine disrupting chemicals in breast cancer: Expert panel recommendations. Reprod Toxicol, 2015, 54: 141-147.
18.	Daly MB, Pal T, Berry MP, et al. Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2. 2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2021, 19(1): 77-102.
19.	Bevers TB, Helvie M, Bonaccio E, et al. Breast cancer screening and diagnosis, version 3. 2018, NCCN clinical pcractice guidelines in oncology. J Natl Compr Canc Netw, 2018, 16(11): 1362-1389.
20.	Owens DK, Davidson KW, Krist AH, et al. Risk assessment, genetic vounseling, and henetic testing for BRCA-related cancer: US preventive services Task force recommendation statement. JAMA, 2019, 322(7): 652-665.
21.	Shieh Y, Tice JA. Medications for primary prevention of breast cancer. JAMA, 2020, 324(3): 291-292.
22.	Yang Y, Pan L, Shao Z. Trend and survival benefit of contralateral prophylactic mastectomy among men with stage Ⅰ-Ⅲ unilateral breast cancer in the USA, 1998-2016. Breast Cancer Res Treat, 2021, 190(3): 503-515.
23.	Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst, 2001, 93(21): 1633-1637.
24.	Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the women's health initiative randomized controlled trial. JAMA, 2002, 288(3): 321-33.
25.	Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med, 2007, 356(16): 1670-1674.
26.	Coombs NJ, Cronin KA, Taylor RJ, et al. The impact of changes in hormone therapy on breast cancer incidence in the US population. Cancer Causes Control, 2010, 21(1): 83-90.
27.	Parkin DM. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer, 2009, 45(9): 1649-1653.
28.	Liu LY, Wang YJ, Wang F, et al. Factors associated with insufficient awareness of breast cancer among women in Northern and Eastern China: A case-control study. BMJ Open, 2018, 8(2): e018523.
29.	陳萬青, 李霓, 石菊芳, 等. 中國城市癌癥早診早治項目進展. 中國腫瘤, 2019, 28(1): 23-25.
30.	黃靜, 楊湘紅, 劉愛, 等. 農村地區婦女“兩癌篩查”項目實施中的問題與對策. 中國全科醫學, 2020, 23(13): 1680-1686.
31.	赫捷, 陳萬青, 李霓, 等. 中國女性乳腺癌篩查與早診早治指南(2021, 北京). 中國腫瘤, 2021, 30(3): 161-191.
32.	Zhao ZZ. Reexamining China’s fertility puzzle: Data collection and quality over the last two decades. Popul Dev Rev, 2006, 32(2): 293-321.
33.	Kobayashi S, Sugiura H, Ando Y, et al. Reproductive history and breast cancer risk. Breast Cancer, 2012, 19(4): 302-308.
34.	Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
35.	Lei S, Zheng R, Zhang S, et al. Breast cancer incidence and mortality in women in China: Temporal trends and projections to 2030. Cancer Biol Med, 2021, 18(3): 900-909.
36.	Loibl S, Poortmans P, Morrow M, et al. Breast cancer. Lancet, 2021, 397(10286): 1750-1769.
37.	Chen C, Sun S, Yuan JP, et al. Characteristics of breast cancer in Central China, literature review and comparison with USA. Breast, 2016, 30: 208-213.
38.	莫淼, 袁晶, 周昌明, 等. 以大型單中心的醫院登記為基礎的3.5萬例乳腺癌患者長期生存報告 . 中國癌癥雜志, 2020, 30(2): 90-97.
39.	中國抗癌協會乳腺癌專業委員會. 中國抗癌協會乳腺癌診治指南與規范(2021年版). 中國癌癥雜志, 2021, 8(31): 770-856.
40.	鄭榮壽, 孫可欣, 張思維, 等. 2015年中國惡性腫瘤流行情況分析. 中華腫瘤雜志, 2019, 41(1): 19-28.
41.	曹毛毛, 陳萬青. 中國惡性腫瘤流行情況及防控現狀. 中國腫瘤臨床, 2019, 46(3): 145-149.
42.	Autier P, Boniol M, La Vecchia C, et al. Disparities in breast cancer mortality trends between 30 European countries: Retrospective trend analysis of WHO mortality database. BMJ, 2010, 341: c3620.
43.	Michael G, Vinod R. Epidemiology, screening and diagnosis of breast cancer in the Asia–Pacific region: Current perspectives and important considerations. Asia-Pac J Clin Oncol, 2008, 4(s3): S5-S13.
44.	Song QK, Li J, Huang R, et al. Age of diagnosis of breast cancer in China: Almost 10 years earlier than in the United States and the European Union. Asian Pac J Cancer Prev, 2014, 15(22): 10021-10025.
45.	Yu ZG, Jia CX, Liu LY, et al. The prevalence and correlates of breast cancer among women in Eastern China. PLoS One, 2012, 7(6): e37784.
46.	Mizukoshi MM, Hossian SZ, Poulos A. Comparative analysis of breast cancer incidence rates between australia and Japan: Screening target implications. Asian Pac J Cancer Prev, 2020, 21(7): 2123-2129.
47.	Sechopoulos I, Mann RM. Stand-alone artificial intelligence - The future of breast cancer screening? Breast, 2020, 49: 254-260.
48.	瞿亞軍, 呂青. 我國乳腺癌預防若干問題的思考. 中國普外基礎與臨床雜志, 2020, 27(11): 1334-1339.
49.	呂青, 瞿亞軍. 乳腺良性疾病與乳腺癌風險. 中國普外基礎與臨床雜志, 2020, 27(11): 1329-1333.

1. Bray F, Laversanne M, Weiderpass E, et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer, 2021, 127(16): 3029-3030.
2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
3. Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (Lond), 2021, 41(11): 1183-1194.
4. 鄒小農, 賈漫漫, 王鑫, 等. 《2020全球癌癥報告》要點解讀. 中國胸心血管外科臨床雜志, 2021, 28(1): 11-18.
5. United Nations Development Program. Human Development Report 2018: Human Development for Everyone. New York, NY: United Nations Development Program, 2018. 22-33.
6. Soerjomataram I, Bray F. Planning for tomorrow: Global cancer incidence and the role of prevention 2020-2070. Nat Rev Clin Oncol, 2021, 18(10): 663-672.
7. Lawson MB, Lee CI, Hippe DS, et al. Receipt of screening mammography by insured women diagnosed with breast cancer and impact on outcomes. J Natl Compr Canc Netw, 2021, Online ahead of print.
8. Duffy SW, Vulkan D, Cuckle H, et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): Final results of a randomised, controlled trial. Lancet Oncol, 2020, 21(9): 1165-1172.
9. Harkness EF, Astley SM, Evans DG. Risk-based breast cancer screening strategies in women. Best Pract Res Clin Obstet Gynaecol, 2020, 65: 3-17.
10. Kresovich JK, Xu Z, O'Brien KM, et al. Methylation-based biological age and breast cancer risk. J Natl Cancer Inst, 2019, 111(10): 1051-1058.
11. Pfeiffer RM, Webb-Vargas Y, Wheeler W, et al. Proportion of U. S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev, 2018, 27(10): 1214-1222.
12. Nguyen TL, Li S, Dite GS, et al. Interval breast cancer risk associations with breast density, family history and breast tissue aging. Int J Cancer, 2020, 147(2): 375-382.
13. Kim YY, Kang HJ, Ha S, et al. Effects of living in the same region as one’s workplace on the total fertility rate of working women in Korea. Epidemiol Health, 2019, 41: e2019043.
14. Zhang Q, Liu LY, Wang F, et al. The changes in female physical and childbearing characteristics in China and potential association with risk of breast cancer. BMC Public Health, 2012, 12: 368.
15. Gray JM, Rasanayagam S, Engel C, et al. State of the evidence 2017: An update on the connection between breast cancer and the environment. Environ Health, 2017, 16(1): 94.
16. Rudel RA, Fenton SE, Ackerman JM, et al. Environmental exposures and mammary gland development: State of the science, public health implications, and research recommendations. Environ Health Perspect, 2011, 119(8): 1053-1061.
17. Teitelbaum SL, Belpoggi F, Reinlib L. Advancing research on endocrine disrupting chemicals in breast cancer: Expert panel recommendations. Reprod Toxicol, 2015, 54: 141-147.
18. Daly MB, Pal T, Berry MP, et al. Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2. 2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2021, 19(1): 77-102.
19. Bevers TB, Helvie M, Bonaccio E, et al. Breast cancer screening and diagnosis, version 3. 2018, NCCN clinical pcractice guidelines in oncology. J Natl Compr Canc Netw, 2018, 16(11): 1362-1389.
20. Owens DK, Davidson KW, Krist AH, et al. Risk assessment, genetic vounseling, and henetic testing for BRCA-related cancer: US preventive services Task force recommendation statement. JAMA, 2019, 322(7): 652-665.
21. Shieh Y, Tice JA. Medications for primary prevention of breast cancer. JAMA, 2020, 324(3): 291-292.
22. Yang Y, Pan L, Shao Z. Trend and survival benefit of contralateral prophylactic mastectomy among men with stage Ⅰ-Ⅲ unilateral breast cancer in the USA, 1998-2016. Breast Cancer Res Treat, 2021, 190(3): 503-515.
23. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst, 2001, 93(21): 1633-1637.
24. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the women's health initiative randomized controlled trial. JAMA, 2002, 288(3): 321-33.
25. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med, 2007, 356(16): 1670-1674.
26. Coombs NJ, Cronin KA, Taylor RJ, et al. The impact of changes in hormone therapy on breast cancer incidence in the US population. Cancer Causes Control, 2010, 21(1): 83-90.
27. Parkin DM. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer, 2009, 45(9): 1649-1653.
28. Liu LY, Wang YJ, Wang F, et al. Factors associated with insufficient awareness of breast cancer among women in Northern and Eastern China: A case-control study. BMJ Open, 2018, 8(2): e018523.
29. 陳萬青, 李霓, 石菊芳, 等. 中國城市癌癥早診早治項目進展. 中國腫瘤, 2019, 28(1): 23-25.
30. 黃靜, 楊湘紅, 劉愛, 等. 農村地區婦女“兩癌篩查”項目實施中的問題與對策. 中國全科醫學, 2020, 23(13): 1680-1686.
31. 赫捷, 陳萬青, 李霓, 等. 中國女性乳腺癌篩查與早診早治指南(2021, 北京). 中國腫瘤, 2021, 30(3): 161-191.
32. Zhao ZZ. Reexamining China’s fertility puzzle: Data collection and quality over the last two decades. Popul Dev Rev, 2006, 32(2): 293-321.
33. Kobayashi S, Sugiura H, Ando Y, et al. Reproductive history and breast cancer risk. Breast Cancer, 2012, 19(4): 302-308.
34. Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
35. Lei S, Zheng R, Zhang S, et al. Breast cancer incidence and mortality in women in China: Temporal trends and projections to 2030. Cancer Biol Med, 2021, 18(3): 900-909.
36. Loibl S, Poortmans P, Morrow M, et al. Breast cancer. Lancet, 2021, 397(10286): 1750-1769.
37. Chen C, Sun S, Yuan JP, et al. Characteristics of breast cancer in Central China, literature review and comparison with USA. Breast, 2016, 30: 208-213.
38. 莫淼, 袁晶, 周昌明, 等. 以大型單中心的醫院登記為基礎的3.5萬例乳腺癌患者長期生存報告 . 中國癌癥雜志, 2020, 30(2): 90-97.
39. 中國抗癌協會乳腺癌專業委員會. 中國抗癌協會乳腺癌診治指南與規范(2021年版). 中國癌癥雜志, 2021, 8(31): 770-856.
40. 鄭榮壽, 孫可欣, 張思維, 等. 2015年中國惡性腫瘤流行情況分析. 中華腫瘤雜志, 2019, 41(1): 19-28.
41. 曹毛毛, 陳萬青. 中國惡性腫瘤流行情況及防控現狀. 中國腫瘤臨床, 2019, 46(3): 145-149.
42. Autier P, Boniol M, La Vecchia C, et al. Disparities in breast cancer mortality trends between 30 European countries: Retrospective trend analysis of WHO mortality database. BMJ, 2010, 341: c3620.
43. Michael G, Vinod R. Epidemiology, screening and diagnosis of breast cancer in the Asia–Pacific region: Current perspectives and important considerations. Asia-Pac J Clin Oncol, 2008, 4(s3): S5-S13.
44. Song QK, Li J, Huang R, et al. Age of diagnosis of breast cancer in China: Almost 10 years earlier than in the United States and the European Union. Asian Pac J Cancer Prev, 2014, 15(22): 10021-10025.
45. Yu ZG, Jia CX, Liu LY, et al. The prevalence and correlates of breast cancer among women in Eastern China. PLoS One, 2012, 7(6): e37784.
46. Mizukoshi MM, Hossian SZ, Poulos A. Comparative analysis of breast cancer incidence rates between australia and Japan: Screening target implications. Asian Pac J Cancer Prev, 2020, 21(7): 2123-2129.
47. Sechopoulos I, Mann RM. Stand-alone artificial intelligence - The future of breast cancer screening? Breast, 2020, 49: 254-260.
48. 瞿亞軍, 呂青. 我國乳腺癌預防若干問題的思考. 中國普外基礎與臨床雜志, 2020, 27(11): 1334-1339.
49. 呂青, 瞿亞軍. 乳腺良性疾病與乳腺癌風險. 中國普外基礎與臨床雜志, 2020, 27(11): 1329-1333.

Next Article
Insights into the clinical studies related to cardiovascular surgery from the American Heart Association’s Scientific Sessions 2021: Part one

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Interpretation of the global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content